Dr Li’s team concluded that “patients with SLE-TMA exhibit a progressive decline of patient and renal survival in the long-term. Prompt diagnosis and risk stratification based on identified risk ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.

Margrit Wiesendanger, MD, PhD, highlights how social determinants of health and equitable treatment access are critical to improving lupus outcomes, particularly in minority populations.

Dr Zenator Agyemang Rawlings, the Member of Parliament (MP) for Korle Klottey, has expressed commitment to leading a ...

A woman with an erratic lifestyle and history of alcohol misuse bled to death in her home after unpicking a dialysis graft ...

A Melbourne hospital has successfully treated an incurable auto-immune condition with a “game-changing” cancer therapy for ...

Roughly 26% of patients with LN demonstrated a responsive and monophasic disease course, which was linked to older age and shorter SLE duration at LN onset.

Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy Targeting Lupus Nephritis, Systemic Lupus Erythematosus and Multiple Sclerosis < ...

WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) ...

LOS ANGELES, May 06, 2025--(BUSINESS WIRE)--Lupus LA is proud to announce the 2025 Patient Advocacy Panel, welcoming two new patient leaders to further amplify diverse voices and lived experiences ...

Cuisine for a Cause, presented with the support of Paramount Pictures ... for a Cause will directly support Lupus LA’s programs dedicated to patient advocacy, community services, and funding ...